Exploring Small-Molecule Inhibitors of Glucosidase II: Advances, Challenges, and Therapeutic Potential in Cancer and Viral Infection
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262411867 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Tay Zar Myo Oo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Chemistry, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Th…. Hauptthemen laut MEDLINE: Neoplasms, Virus Diseases, Glycoside Hydrolase Inhibitors, alpha-Glucosidases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chiang Mai University, Chiang Mai University Presidential Scholarship, National Research Council of Thailand.
Abstract (Originalsprache)
Glucosidase II (GluII) is a heterodimeric enzyme localized in the endoplasmic reticulum (ER), essential for the sequential trimming of glucose residues during N-linked glycosylation. This critical function facilitates glycoprotein folding via the calnexin/calreticulin chaperone system, maintaining ER homeostasis. Dysregulation or inhibition of GluII has been implicated in various pathological processes, including cancer, viral infections, and glycoprotein misfolding disorders. This review summarizes the current knowledge of GluII’s structure and function, highlights a wide range of natural and synthetic GluII inhibitors—including iminosugar derivatives (e.g., deoxynojirimycin (DNJ), castanospermine (CAST)), non-iminosugar compounds (e.g., bromoconduritol, catechins), and mechanism-based cyclophellitol analogues—and evaluates their biological effects and therapeutic potential. The cellular impact of GluII inhibition is explored in the context of ER stress, unfolded protein response (UPR), tumor cell apoptosis, and viral replication. Key challenges in developing selective GluII inhibitors are discussed, with a focus on strategies to minimize off-target effects, including prodrug design, allosteric modulation, and emerging genetic approaches such as microRNA (miRNA)-mediated downregulation of GluII subunits. Taken together, these insights underscore the therapeutic relevance of GluII as a druggable target and pave the way for the rational design of next-generation inhibitors in oncology, infectious diseases, and metabolic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Chemistry, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.
- Division of Transfusion Sciences, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.
ORCID-Profile: Yupanun Wuttiin, Ratchada Cressey
Förderung
- Chiang Mai University
- Chiang Mai University Presidential Scholarship
- National Research Council of Thailand
Zitieren
APA
Oo, T. Z. M., Wuttiin, Y., Choocheep, K., Kumsaiyai, W., Bunpo, P., & Cressey, R. (2025). Exploring Small-Molecule Inhibitors of Glucosidase II: Advances, Challenges, and Therapeutic Potential in Cancer and Viral Infection. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262411867
Vancouver
Oo TZM, Wuttiin Y, Choocheep K, Kumsaiyai W, Bunpo P, Cressey R. Exploring Small-Molecule Inhibitors of Glucosidase II: Advances, Challenges, and Therapeutic Potential in Cancer and Viral Infection. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262411867
BibTeX
@article{Oo2025,
author = {Oo, Tay Zar Myo and Wuttiin, Yupanun and Choocheep, Kanyamas and Kumsaiyai, Warunee and Bunpo, Piyawan and Cressey, Ratchada},
title = {Exploring Small-Molecule Inhibitors of Glucosidase II: Advances, Challenges, and Therapeutic Potential in Cancer and Viral Infection},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262411867}
}
EUVIMED